Tag: FDA

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial ...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...

Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to ...

Ensysce Biosciences will participate in the U.S. Food and Drug Administration's September 14 public hearing on the potential future therapeutic ...

In 1962, an American chemist quietly created an experimental compound in a laboratory at Parke, Davis & Company. It was ...

While psilocybin and MDMA have dominated the modern psychedelic renaissance, another compound has quietly remained on the sidelines. Ibogaine has ...

The psychedelic medicine sector has spent much of the past decade fighting for scientific credibility, regulatory acceptance, and investor confidence. ...